GSK, Adolor upbeat on Phase IIb Entereg data

GlaxoSmithKline and Adolor are reporting positive data from a Phase IIb study of Entereg (alvimopan) for negating the side effects of opioids like morphine. "Millions of people worldwide take opioids chronically to treat moderate to severe pain and about half of them will suffer from associated constipation, abdominal pain, discomfort and bloating. Constipation can lead to serious complications and in some cases can be life threatening. Often patients cannot receive enough opioid to manage their pain due to constipation. The findings from this study suggest that alvimopan may play an important role in treating these GI side effects in patients by blocking the effects opioids have on the gut without adversely impacting the effect on pain control," said Dr. Lynn Webster, Lifetree Clinical Research and Pain Clinic, Salt Lake City, Utah, USA.

- here's the release on Entereg